Department of Cardiovascular Sciences, University of Leicester, Leicester, UK; Leicester Vascular Institute, University Hospitals of Leicester NHS Trust, Leicester, UK.
NIHR Biomedical Research Unit, University Hospitals of Leicester NHS Trust, Leicester, UK.
Ann Vasc Surg. 2023 Jul;93:157-165. doi: 10.1016/j.avsg.2023.03.032. Epub 2023 Apr 5.
Vascular Emergency Clinics (VEC) improve patient outcomes in chronic limb-threatening ischemia (CLTI). They provide a "1 stop" open access policy, whereby "suspicion of CLTI" by a healthcare professional or patient leads to a direct review. We assessed the resilience of the outpatient VEC model to the first year of the coronavirus disease (COVID-19) pandemic.
A retrospective review of a prospectively maintained database of all patients assessed in our VEC for lower limb pathologies between March 2020 and April 2021 was performed. This was cross-referenced to national and loco-regional Governmental COVID-19 data. Individuals with CLTI were further analysed to determine Peripheral Arterial Disease-Quality Improvement Framework compliance.
Seven hundred and ninety one patients attended for 1,084 assessments (Male n = 484, 61%; Age 72.5 ± standard deviation 12.2 years; White British n = 645, 81.7%). In total, 322 patients were diagnosed with CLTI (40.7%). A total of 188 individuals (58.6%) underwent a first revascularization strategy (Endovascular n = 128, 39.8%; Hybrid n = 41, 12.7%; Open surgery n = 19, 5.9%; Conservative n = 134, 41.6%). Major lower limb amputation rate was 10.9% (n = 35) and mortality rate was 25.8% (n = 83) at 12 months of follow-up. Median referral to assessment time was 3 days (interquartile range: 1-5). For the nonadmitted patient with CLTI, the median assessment to intervention was 8 days (interquartile range: 6-15) and median referral to intervention time of 11 days (11-18).
The VEC model has demonstrated strong resilience to the COVID-19 pandemic with rapid treatment timelines maintained for patients with CLTI.
血管急症诊所(VEC)改善了慢性肢体威胁性缺血(CLTI)患者的预后。它们提供了“一站式”的开放准入政策,即医疗保健专业人员或患者对 CLTI 的“怀疑”会直接进行评估。我们评估了门诊 VEC 模式在冠状病毒病(COVID-19)大流行第一年的适应能力。
对 2020 年 3 月至 2021 年 4 月期间在我们的 VEC 中评估下肢病变的所有患者的前瞻性维护数据库进行了回顾性分析。这与国家和地方政府的 COVID-19 数据进行了交叉参考。进一步分析了 CLTI 患者,以确定外周动脉疾病质量改进框架的合规性。
791 名患者接受了 1084 次评估(男性 n=484,61%;年龄 72.5±标准偏差 12.2 岁;白种英国人 n=645,81.7%)。共有 322 名患者被诊断为 CLTI(40.7%)。共有 188 人(58.6%)接受了首次血管重建策略(血管内 n=128,39.8%;杂交 n=41,12.7%;开放手术 n=19,5.9%;保守治疗 n=134,41.6%)。12 个月随访时,主要下肢截肢率为 10.9%(n=35),死亡率为 25.8%(n=83)。从转诊到评估的中位时间为 3 天(四分位间距:1-5)。对于非住院的 CLTI 患者,评估到干预的中位时间为 8 天(四分位间距:6-15),转诊到干预的中位时间为 11 天(11-18)。
VEC 模式在 COVID-19 大流行期间表现出很强的适应能力,为 CLTI 患者保持了快速的治疗时间线。